Carlos E RodrÃ-guez-MartÃ-nez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8407104/publications.pdf

Version: 2024-02-01



Carlos E

#	Article	IF	CITATIONS
1	Are we overcoming our inability to have pediatric patients properly use inhaled corticosteroids by inappropriately escalating their therapy?. Journal of Asthma, 2022, 59, 1360-1371.	1.7	3
2	Use of inhaled corticosteroids on an intermittent or as-needed basis inÂpediatric asthma: a systematic review of the literature. Journal of Asthma, 2022, 59, 2189-2200.	1.7	2
3	Predictors of poor outcomes of respiratory syncytial virus acute lower respiratory infections in children under 5 years of age in a middleâ€income tropical country based on the National Public Health Surveillance System. Pediatric Pulmonology, 2022, 57, 1188-1195.	2.0	4
4	As-Needed Use of Short-Acting β2-Agonists Alone Versus As-Needed Use of Short-Acting β2-Agonists Plus Inhaled Corticosteroids in Pediatric Patients With Mild Intermittent (Step 1) Asthma: A Cost-Effectiveness Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1562-1568.	3.8	2
5	Disease burden and vaccination priorities in Colombia. Vaccine, 2022, 40, 1717-1721.	3.8	1
6	Emergency departmentâ€initiated home oxygen for viral bronchiolitis: A costâ€effectiveness analysis. Pediatric Pulmonology, 2022, 57, 2154-2160.	2.0	1
7	A comparative analysis of the bronchodilatador response measured by impulse oscillometry and spirometry in asthmatic children living at high altitude. Journal of Asthma, 2021, 58, 1488-1494.	1.7	2
8	Nebulization procedures for children with unknown viral status during the COVID-19 pandemic. Journal of Asthma, 2021, 58, 1597-1598.	1.7	1
9	Commercial valved spacers versus home-made spacers for delivering bronchodilator therapy in pediatric acute asthma: a cost-effectiveness analysis. Journal of Asthma, 2021, 58, 1340-1347.	1.7	2
10	Costâ€effectiveness analysis of phenotypicâ€guided versus guidelinesâ€guided bronchodilator therapy in viral bronchiolitis. Pediatric Pulmonology, 2021, 56, 187-195.	2.0	4
11	For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?. Allergologia Et Immunopathologia, 2021, 49, 153-158.	1.7	10
12	Prediction of normal values for central apnea-hypopnea index at different ages and altitudes above sea level in healthy children. Sleep Medicine, 2021, 78, 182-188.	1.6	2
13	Airway Remodeling Factors During Early-Life Rhinovirus Infection and the Effect of Premature Birth. Frontiers in Pediatrics, 2021, 9, 610478.	1.9	11
14	When adherence and inhalation technique matter: Difficultâ€toâ€control pediatric asthma in low―to middleâ€income countries. Pediatric Pulmonology, 2021, 56, 1366-1373.	2.0	5
15	Early Microbial–Immune Interactions and Innate Immune Training of the Respiratory System during Health and Disease. Children, 2021, 8, 413.	1.5	10
16	Budget impact analysis of high-flow nasal cannula for infant bronchiolitis: the Colombian National Health System perspective. Current Medical Research and Opinion, 2021, 37, 1627-1632.	1.9	5
17	Costâ€utility of omalizumab for the treatment of uncontrolled moderateâ€ŧoâ€severe persistent pediatric allergic asthma in a middleâ€income country. Pediatric Pulmonology, 2021, 56, 2987-2996.	2.0	6
18	Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: A cost-utility analysis in Colombia. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3816-3818.e2.	3.8	8

CARLOS E

#	Article	IF	CITATIONS
19	Response to letter. Pediatric Pulmonology, 2021, 56, 2783-2784.	2.0	0
20	Cost utility of fractional exhaled nitric oxide monitoring for the management of children asthma. Cost Effectiveness and Resource Allocation, 2021, 19, 33.	1.5	12
21	Costâ€utility of tiotropium for children with severe asthma in patients aged 1–5 years. Pediatric Allergy and Immunology, 2021, 32, 1866-1868.	2.6	9
22	Genes, environment, and developmental timing: New insights from translational approaches to understand early origins of respiratory diseases. Pediatric Pulmonology, 2021, 56, 3157-3165.	2.0	4
23	The use of ipratropium bromide for treating moderate to severe asthma exacerbations in pediatric patients in an emergency setting: A costâ€effectiveness analysis. Pediatric Pulmonology, 2021, 56, 3706-3713.	2.0	1
24	To the Editor. Sleep Medicine, 2021, 86, 124.	1.6	0
25	Characterization of the variability of care for acute severe asthma: An opportunity for quality improvement initiatives. Pediatric Pulmonology, 2021, 56, 809-810.	2.0	1
26	Validation of a Spanish version of the Sleepâ€Related Breathing Disorder scale of the Pediatric Sleep Questionnaire in children living in a highâ€altitude city. Pediatric Pulmonology, 2021, 56, 1077-1084.	2.0	3
27	The cost-utility of early use of high-flow nasal cannula in bronchiolitis. Health Economics Review, 2021, 11, 41.	2.0	9
28	Advantage of inhaled corticosteroids as additional therapy to systemic corticosteroids for pediatric acute asthma exacerbations: a cost-effectiveness analysis. Journal of Asthma, 2020, 57, 949-958.	1.7	7
29	The impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?. Paediatric Respiratory Reviews, 2020, 34, 53-58.	1.8	14
30	Bedside clinical assessment predicts recurrence after hospitalization due to viral lower respiratory tract infection in young children. Journal of Investigative Medicine, 2020, 68, 756-761.	1.6	4
31	Impact of pulmonary hypertension and congenital heart disease with hemodynamic repercussion on the severity of acute respiratory infections in children under 5 years of age at a pediatric referral center in Colombia, South America. Cardiology in the Young, 2020, 30, 1866-1873.	0.8	3
32	The use of β ₂ -adrenoreceptor agonists in viral bronchiolitis: scientific rationale beyond evidence-based guidelines. ERJ Open Research, 2020, 6, 00135-2020.	2.6	9
33	Adding nebulized corticosteroids to systemic corticosteroids for acute asthma in children: A systematic review with metaâ€analysis. Pediatric Pulmonology, 2020, 55, 2508-2517.	2.0	3
34	Development of spirometric reference equations for children living at high altitude. Clinical Respiratory Journal, 2020, 14, 1011-1017.	1.6	1
35	Meteredâ€dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with metaâ€analysis. Pediatric Pulmonology, 2020, 55, 3268-3278.	2.0	11
36	The costâ€utility of intravenous magnesium sulfate for treating asthma exacerbations in children. Pediatric Pulmonology, 2020, 55, 2610-2616.	2.0	11

Carlos E

#	Article	IF	CITATIONS
37	Dexamethasone or prednisolone for asthma exacerbations in children: A costâ€effectiveness analysis. Pediatric Pulmonology, 2020, 55, 1617-1623.	2.0	4
38	Efficacy, safety and costâ€effectiveness of hydroxychloroquine in children with COVIDâ€19: A call for evidence. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 1711-1712.	1.5	4
39	Decontamination and reuse of N95 filtering facemask respirators: A systematic review of the literature. American Journal of Infection Control, 2020, 48, 1520-1532.	2.3	87
40	Meteredâ€dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A costâ€effectiveness analysis in a middleâ€income country. Pediatric Pulmonology, 2020, 55, 866-873.	2.0	13
41	Validation of a new predictive model to improve risk stratification in bronchopulmonary dysplasia. Scientific Reports, 2020, 10, 613.	3.3	7
42	Phenotypical Sub-setting of the First Episode of Severe Viral Respiratory Infection Based on Clinical Assessment and Underlying Airway Disease: A Pilot Study. Frontiers in Pediatrics, 2020, 8, 121.	1.9	12
43	Predictors of response to medications for asthma in pediatric patients: A systematic review of the literature. Pediatric Pulmonology, 2020, 55, 1320-1331.	2.0	7
44	Costâ€effectiveness of the utilization of "good practice―or the lack thereof according to a bronchiolitis evidenceâ€based clinical practice guideline. Journal of Evaluation in Clinical Practice, 2019, 25, 682-688.	1.8	5
45	Reference values for spirometric parameters in healthy children living in a Colombian city located at 2640 m altitude. Pediatric Pulmonology, 2019, 54, 886-893.	2.0	5
46	The relationship between inflammation and remodeling in childhood asthma: A systematic review. Pediatric Pulmonology, 2018, 53, 824-835.	2.0	47
47	Predictors of Prolonged Length of Hospital Stay for Infants with Bronchiolitis. Journal of Investigative Medicine, 2018, 66, 986-991.	1.6	17
48	Systematic review of instruments aimed at evaluating the severity of bronchiolitis. Paediatric Respiratory Reviews, 2018, 25, 43-57.	1.8	18
49	Predictors of prolonged length of hospital stay or readmissions for acute viral lower respiratory tract infections among infants with a history of bronchopulmonary dysplasia. Journal of Medical Virology, 2018, 90, 405-411.	5.0	9
50	Clinical Definition of Respiratory Viral Infections in Young Children and Potential Bronchiolitis Misclassification. Journal of Investigative Medicine, 2018, 66, 46-51.	1.6	20
51	Phenotypical characterization of human rhinovirus infections in severely premature children. Pediatrics and Neonatology, 2018, 59, 244-250.	0.9	6
52	A cost-effectiveness threshold analysis of a multidisciplinary structured educational intervention in pediatric asthma. Journal of Asthma, 2018, 55, 561-570.	1.7	4
53	Predictors of hospitalization for acute lower respiratory infections during the first two years of life in a population of preterm infants with bronchopulmonary dysplasia. Early Human Development, 2018, 127, 53-57.	1.8	9
54	Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatric Pulmonology, 2018, 53, 1670-1677.	2.0	34

CARLOS E

IF # ARTICLE CITATIONS Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patient's With Mild to Moderate Hypertension: The VACLOR Study. Clinical Medicine Insights: 1.8 Cardiology, 2018, 12, 117954681879648. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. Pharmacoeconomics, 2018, 36, 1165-1200. 56 3.3 21 A systematic review of instruments aimed at evaluating metered-dose inhaler administration 1.7 technique in children. Journal of Asthma, 2017, 54, 173-185. Quality assessment of acute viral bronchiolitis clinical practice guidelines. Journal of Evaluation in 58 1.8 8 Clinical Practice, 2017, 23, 37-43. Predictors of Inappropriate Use of Diagnostic Tests and Management of Bronchiolitis. BioMed 1.9 Research International, 2017, 2017, 1-6. Factors predicting persistence of early wheezing through childhood and adolescence: a systematic review of the literature. Journal of Asthma and Allergy, 2017, Volume10, 83-98. 60 3.4 42 Age-Related Effect of Viral-Induced Wheezing in Severe Prematurity. Children, 2016, 3, 19. 1.5 Predictors of severe disease in a hospitalized population of children with acute viral lower 62 5.0 14 respiratory tract infections. Journal of Medical Virology, 2016, 88, 754-759. Costâ€"utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance 1.7 treatment of asthma in pediatric patients. Journal of Asthma, 2016, 53, 538-545. Impact of the implementation of an evidence-based guideline on diagnostic testing, management, and 64 clinical outcomes for infants with bronchiolitis. Therapeutic Advances in Respiratory Disease, 2016, 2.6 16 10, 425-434. Risk and Protective Factors for Childhood Asthma: What Is the Evidence?. Journal of Allergy and 3.8 Clinical Immunology: in Practice, 2016, 4, 1111-1122. Human Metapneumovirus Infection is Associated with Severe Respiratory Disease in Preschool 0.9 66 16 Children with History of Prematurity. Pediatrics and Neonatology, 2016, 57, 27-34. Leukotriene receptor antagonists as maintenance or intermittent treatment in pre-school children 1.8 with episodic viral wheeze. Paediatric Respiratory Reviews, 2016, 17, 57-59. Bronchodilators should be considered for all patients with acute bronchiolitis, but closely monitored for objectively measured clinicalÂbenefits. Acta Paediatrica, International Journal of 68 1.5 14 Paediatrics, 2015, 104, 858-860. Children under 12 months could benefit from a therapeutic trial with bronchodilators if the clinical 1.5 response is positive. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, e540-e540. Respiratory syncytial virus, adenoviruses, and mixed acute lower respiratory infections in children in 70 5.0 27 a developing country. Journal of Medical Virology, 2015, 87, 774-781. Principal findings of systematic reviews for the management of acute bronchiolitis in children. 71 1.8 Paediatric Respiratory Reviews, 2015, 16, 267-275. Premature infants have impaired airway antiviral IFNÎ³ responses to human metapneumovirus compared 72 2.3 26 to respiratory syncytial virus. Pediatric Research, 2015, 78, 389-394.

Carlos E

#	Article	IF	CITATIONS
73	Cost-Effectiveness Analysis of Mometasone Furoate Versus Beclomethasone Dipropionate for the Treatment of Pediatric Allergic Rhinitis in Colombia. Advances in Therapy, 2015, 32, 254-269.	2.9	8
74	Validation of the Spanish version of the Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ) in a population of Hispanic children. Journal of Asthma, 2015, 52, 749-754.	1.7	5
75	Principal findings of systematic reviews of acute asthma treatment in childhood. Journal of Asthma, 2015, 52, 1038-1045.	1.7	20
76	Principal findings of systematic reviews for chronic treatment in childhood asthma. Journal of Asthma, 2015, 52, 407-416.	1.7	13
77	Costâ€utility analysis of daily versus intermittent inhaled corticosteroids in mildâ€persistent asthma. Pediatric Pulmonology, 2015, 50, 735-746.	2.0	18
78	Characterization of Cytomegalovirus Lung Infection in Non-HIV Infected Children. Viruses, 2014, 6, 2038-2051.	3.3	27
79	Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region. Pediatric Pulmonology, 2014, 49, 269-276.	2.0	72
80	Predictors of hospitalization for asthma in children: Results of a 1-year prospective study. Pediatric Pulmonology, 2014, 49, 1058-1064.	2.0	16
81	Validation of the Spanish Version of the Test for Respiratory and Asthma Control in Kids (TRACK) in a Population of Hispanic Preschoolers. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 326-331.e3.	3.8	12
82	Validation of the Spanish version of the childhood asthma control test (cACT) in a population of Hispanic children. Journal of Asthma, 2014, 51, 855-862.	1.7	16
83	Cost-Utility Analysis of the Inhaled Steroids Available in a Developing Country for the Management of Pediatric Patients with Persistent Asthma. Journal of Asthma, 2013, 50, 410-418.	1.7	35
84	Comparison of the bronchodilating effects of albuterol delivered by valved vs. nonâ€valved spacers in pediatric asthma. Pediatric Allergy and Immunology, 2012, 23, 629-635.	2.6	5
85	Discriminative properties of two predictive indices for asthma diagnosis in a sample of preschoolers with recurrent wheezing. Pediatric Pulmonology, 2011, 46, 1175-1181.	2.0	40
86	Prevalence of and factors associated with current asthma symptoms in school children aged 6–7 and 13–14 yr old in BogotÃi, Colombia. Pediatric Allergy and Immunology, 2008, 19, 307-314.	2.6	49
87	Commercial versus home-made spacers in delivering bronchodilator therapy for acute therapy in children. The Cochrane Library, 2008, , CD005536.	2.8	12